A diagnosis of breast cancer, the most common cancer worldwide, is life changing for patients, their families and loved ones. Listening and learning from their real-life experiences is key. We are working on improving access to and participation by patient populations who are often underrepresented in clinical trials, identifying new pathways or mutations that may play a role in disease progression and developing therapies with a goal of extending and improving the lives of those with breast cancer.
More men are receiving a diagnosis of prostate cancer than ever before. At Novartis, we are harnessing the innovation of our world-class scientists, strategic partnerships, and one of the industry’s most competitive pipelines to make the promise of next-generation medicines a reality to address unmet needs in care.
Globally, more than 2 million people are diagnosed with lung cancer each year, and each one has a unique experience that must be considered. Through cutting-edge science and technology, we are finding new ways to explore therapies with a goal of improving outcomes for each individual with lung cancer.
Innovative therapies introduced over the past two decades have revolutionized treatment for people with CML, a serious and life-threatening blood disorder. Even with the innovations seen in this space, some patients still experience resistance and/or intolerance to currently available therapies, which means that CML can remain a devastating diagnosis. More work needs to be done to turn scientific breakthroughs into medicines so that more people can benefit from life-changing medicines.
Even though neuroendocrine tumors (NETs) are considered slow-growing malignancies, people with this type of cancer can experience rapid progression and poor prognosis. In many cases, diagnosis is delayed until patients have advanced disease, often making the impact of the disease more devastating. Even though NETs are considered rare, the number of people affected has grown over 500% in the last three decades, reinforcing the need for innovative treatment options for those who are newly diagnosed with inoperable or advanced cancer.
Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash
Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors
Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard‐of‐care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia
Facing the fear of breast cancer recurrence
Patient Perspectives Facing the fear of breast cancer recurrence When Laurie Brunner found a lump in her breast just before Thanksgiving in 2018, it was the beginning of one of the most difficult periods of her life. Although treatment put her cancer into remission, she found herself dealing with an emotional toll that affects many survivors of early-stage breast cancer: the fear of it coming back.
When you think of the word ‘cancer’, what are the first words that spring to mind?
Fighter. Hero. Cancer-stricken. The words and metaphors people use to talk about cancer often feel worlds apart from any other disease. But how far does it go? Do words matter?
Prostate cancer and support of the care partner – Carl and Arlene’s story - Let’s Talk About The C-Word
When Carl was diagnosed with metastatic prostate cancer, he and his wife Arlene began navigating his cancer journey while still looking to enjoy their retirement – hoping to remain active with family and friends in their retirement community.
Helping people solve problems
1:1 with Reshema Kemps-Polanco – Executive Vice President, Oncology IM US.
Let’s Talk About The C-Word
Leanne Pero discusses her experiences of life before, during and after breast cancer, and how it inspired her to advocate for herself and others like her.
Novartis commits to addressing racial disparities in breast cancer screening, treatment and care
Novartis today announced the launch of More Than Just Words, a multiyear commitment to promote health equity in breast cancer care, where there is significant unmet need. Black women under the age of 35 are diagnosed with breast cancer at twice the rate of white women the same age.
Events and scientific meetings
|American Association for Cancer Research
|American Society of Clinical Oncology
|American Society of Clinical Oncology, Gastrointestinal Cancers
|American Society of Clinical Oncology, Genitourinary Cancers
|American Society of Hematology
|American Urological Association
|European Association of Nuclear Medicine
|European Association of Urology
|European Hematology Association
|Formerly the European Society for Blood and Marrow Transplantation
|European Neuroendocrine Tumor Society
|European Society For Medical Oncology International Association of the Study of Lung Cancer
|San Antonio Breast Cancer Symposium
Other therapeutic areas
Cardiovascular, renal and metabolic
Transforming how the world tackles cardiovascular disease and delivering new treatments for people with chronic kidney diseases
Working to create a world where the millions of people with immunological conditions, and those who treat them, can live without compromise.
Combining the power of science and empathy to unravel the inner workings of cancer and develop innovative therapies that restore hope to those with cancer and their loved ones.